Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice


Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis1,2. This condition has no cure3 and results in eventual death, usually within 1–5 years of diagnosis1,2. Although the specific etiology of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1)4. Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathology that are very similar to that seen in human ALS patients5,6. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacological activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Effect of arimoclomol on muscle function in 120-d-old SOD1G93A mice.
Figure 2: Neuroprotective effect of arimoclomol in 120-d-old SOD1G93A mice.
Figure 3: Disease signs and lifespan in arimoclomol-treated and untreated SOD1G93A mice.
Figure 4: HSP-70 and Hsf-1 expression in arimoclomol-treated and untreated SOD1G93A mice.


  1. Rowland, L.P. & Shneider, N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344, 1688–1700 (2001).

    CAS  Article  Google Scholar 

  2. Shaw, P.J. Motor neurone disease. Br. Med. J. 318, 1118–1121 (1999).

    CAS  Article  Google Scholar 

  3. Miller, R.G., Mitchell, J.D., Lyon, M. & Moore, D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. CD001447 (2002).

  4. Rosen, D.R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62 (1993).

    CAS  Article  Google Scholar 

  5. Gurney, M.E. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772–1775 (1994).

    CAS  Article  Google Scholar 

  6. Wong, P.C. et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14, 1105–1116 (1995).

    CAS  Article  Google Scholar 

  7. Vigh, L. et al. Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat. Med. 3, 1150–1154 (1997).

    CAS  Article  Google Scholar 

  8. Lindquist, S. The heat-shock response. Annu. Rev. Biochem. 55, 1151–1191 (1986).

    CAS  Article  Google Scholar 

  9. Garofalo, O. et al. Ubiquitin and heat shock protein expression in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 17, 39–45 (1991).

    CAS  Article  Google Scholar 

  10. Vleminckx, V. et al. Upregulation of HSP27 in a transgenic model of ALS. J. Neuropathol. Exp. Neurol. 61, 968–974 (2002).

    CAS  Article  Google Scholar 

  11. Shinder, G.A., Lacourse, M.C., Minotti, S. & Durham, H.D. Mutant Cu/Zn- superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis. J. Biol. Chem. 276, 12791–12796 (2001).

    CAS  Article  Google Scholar 

  12. Okado-Matsumoto, A. & Fridovich, I. Amyotrophic lateral sclerosis: a proposed mechanism. Proc. Natl. Acad. Sci. USA 99, 9010–9014 (2002).

    CAS  Article  Google Scholar 

  13. Kalmar, B. et al. Upregulation of heat shock proteins rescues motoneurones from axotomy-induced cell death in neonatal rats. Exp. Neurol. 176, 87–97 (2002).

    CAS  Article  Google Scholar 

  14. Zhu, S. et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74–78 (2002).

    CAS  Article  Google Scholar 

  15. Dick, J., Greensmith, L. & Vrbova, G. Blocking of NMDA receptors during a critical stage of development reduces the effects of nerve injury at birth on muscles and motoneurones. Neuromuscul. Disord. 5, 371–382 (1995).

    CAS  Article  Google Scholar 

  16. White, C.M., Greensmith, L. & Vrbova, G. Repeated stimuli for axonal growth causes motoneuron death in adult rats: the effect of botulinum toxin followed by partial denervation. Neuroscience 95, 1101–1109 (2000).

    CAS  Article  Google Scholar 

  17. Hargitai, J. et al. Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem. Biophys. Res. Commun. 307, 689–695 (2003).

    CAS  Article  Google Scholar 

  18. Batulan, Z. et al. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J. Neurosci. 23, 5789–5798 (2003).

    CAS  Article  Google Scholar 

  19. Sarge, K.D., Murphy, S.P. & Morimoto, R.I. Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. Mol. Cell Biol. 13, 1392–1407 (1993).

    CAS  Article  Google Scholar 

  20. Morrison, A.J., Rush, S.J. & Brown, I.R. Heat shock transcription factors and the HSP70 induction response in brain and kidney of the hyperthermic rat during postnatal development. J. Neurochem. 75, 363–372 (2000).

    CAS  Article  Google Scholar 

Download references


We thank Biorex R&D (Hungary) for the gift of arimoclomal. L.G. is the Graham Watts Senior Research Fellow funded by the Brain Research Trust. D.K. is in receipt of a Brain Research Trust Prize Studentship.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Linda Greensmith.

Ethics declarations

Competing interests

As a consequence of the work presented in this paper, G.B. and L.G. are named on a patent application by Biorex R & D Co., Hungary.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kieran, D., Kalmar, B., Dick, J. et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10, 402–405 (2004).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing